Sun Pharmaceutical Industries has patented a topical ophthalmic formulation containing cyclosporine for treating inflammatory ocular diseases. The formulation includes specific ingredients and concentrations, offering a potential treatment option for ocular conditions. GlobalData’s report on Sun Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Sun Pharmaceutical Industries, Nanoparticle drug conjugates was a key innovation area identified from patents. Sun Pharmaceutical Industries's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Topical ophthalmic formulation for treating inflammatory ocular disease
A recently granted patent (Publication Number: US11951153B2) discloses a method for treating inflammatory ocular diseases and increasing tear production in subjects. The method involves administering an ophthalmic aqueous topical formulation containing specific ingredients such as cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, povidone, sodium chloride, phosphate buffer, and water. The formulation's pH is adjusted to about 5 to 8 with sodium hydroxide and/or hydrochloric acid. The cyclosporine concentration ranges from 0.087-0.093 wt %, with the administering frequency typically being twice daily.
Furthermore, the patent also covers a method specifically targeting keratoconjunctivitis sicca, a type of inflammatory ocular disease. The treatment regimen involves administering the same ophthalmic aqueous topical formulation twice daily to the subject. The formulation's pH is maintained between 6.6 to 7.0, with the cyclosporine concentration set at 0.09 wt %. This method aims to provide an effective treatment for keratoconjunctivitis sicca by utilizing the specified formulation and administration protocol outlined in the patent.
To know more about GlobalData’s detailed insights on Sun Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
